Novel 1,2,3-triazole-tethered Pam3CAG conjugates as potential TLR-2 agonistic vaccine adjuvants

Mhamane, Tukaram B.; Sambyal, Shainy; Vemireddy, Sravanthi; Khan, Imran; Shafi, Syed; Halmuthur, M. Sampath Kumar

doi:10.1016/j.bioorg.2021.104838

Cited by 9 publications

(3 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The cells were then stained with 5μl of PE-antiCD4, FITC-A antiCD8 and FITC-A antiCD19 flurochrome tagged antibodies for 45 min at 4°C. The pellets so collected were resuspended in sheath fluid and cell population was quantified using BD FACSsuit software [8].…”

Section: Methodsmentioning

confidence: 99%

“…To avoid non-specific binding of Fc receptors chiefly present on B-cells, NK cells, macrophages, dendritic cells with antibodies via their consistent domain, the Fc receptors were blocked with CD1 /32 for 15 min at C. Again cells were washed with 250μl of FAC staining buffer to clear away unbound antibodies. The cells were then stained with 5μl of PE-antiCD4, FITC-A antiCD8 and FITC-A antiCD19 flurochrome tagged antibodies for 45 min at C. The pellets so collected were resuspended in sheath fluid and cell population was quantified using BD FACSsuit software [8].…”

Section: Estimation Of Cd4 Cd8 and Cd19 Markersmentioning

confidence: 99%

See 1 more Smart Citation

Immunopharmacological evaluation of adjuvant efficacy of Monophosphoryl lipid-A and CpG ODN with SARS-CoV-2 RBD antigen

Sambyal

Vemireddy²,

Khatri

et al. 2022

Preprint

Self Cite

View full text Add to dashboard Cite

SARS-CoV-2 infection has made the mankind to witness most sever and serious pandemic situation in the history. Millions of people have suffered and are still suffering with this infection which has caused a mass mortality in the past three years. Development of an effective vaccine to control the spread of infection and to prevent this viral infection is need of the hour. Adjuvanted vaccines have proven their efficacy in controlling many other viral infections like flu, keeping this context in view we have evaluated the immunopharmacological efficacy of two adjuvants MPL-A and CpG ODN in combination with MF59 emulsion against SARS-CoV-2 antigen. From the data obtained we can infer that both the adjuvants were capable of eliciting a potent antibody response against antigen alone and MF59 groups. Comparatively MPL-A was eliciting a Th1 polarized response in terms of IgG2a and cytokine production. Both the adjuvants were capable of enhancing the CD 4, 8 and 19 cell populations. Overall the pre clinical evaluation has given a clue of the effectiveness of MPL-A and CpG adjuvants against SARS-CoV-2 antigen.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Estimation Of Cd4 Cd8 and Cd19 Markersmentioning

confidence: 99%

Immunopharmacological evaluation of adjuvant efficacy of Monophosphoryl lipid-A and CpG ODN with SARS-CoV-2 RBD antigen

Sambyal

Vemireddy²,

Khatri

et al. 2022

Preprint

Self Cite

View full text Add to dashboard Cite

show abstract

“…The crude product was puried by ash chromatography (MeOH/CH 2 Cl 2 ) to afford the desired compound. [16][17][18] Synthesis of compound 9a:…”

Section: Chemical Synthetic Proceduresmentioning

confidence: 99%

Synthesis and immunopharmacological evaluation of novel TLR7 agonistic triazole tethered imidazoquinolines

et al. 2023

Self Cite

View full text Add to dashboard Cite

show abstract

Mono‐Palmitoyl‐N‐Alkylurea Ligands as Specific Activators of Human Toll‐Like Receptor 2/6 Heterodimer

Isendoorn,

Castello,

Koç

et al. 2024

ChemBioChem

View full text Add to dashboard Cite

Ligands for Toll‐like‐receptor 2 (TLR2) have demonstrated significant potential as immune‐stimulating components in synthetic vaccines. Activation of TLR2 relies on the formation of dimeric complexes with either TLR1 or TLR6 and the nature of these dimers can impact therapeutic outcomes. The lipopeptide‐based TLR2 ligands Pam3CysSK4 and Pam2CysSK4 have been extensively studied, and their recognition by different TLR‐receptor heterodimers, TLR2/TLR1 and TLR2/TLR6, respectively, has been established. However, the high lipophilicity of these ligands, containing multiple palmitoyl residues, can result in solubility issues when used as vaccine adjuvants. To address this, we previously synthesized a less lipophilic ligand containing a single palmitoyl chain called mini‐UPam, which effectively stimulates human moDC maturation. We here probe the receptor‐dimer specificity of several mini‐Upam derivatives and reveal that these mini‐UPam are hTLR2/TLR6 selective ligands and that the introduction of longer urea alkyl chains does not shift the binding specificity to hTLR2/TLR1 heterodimers, in contrast to their Pam2CysSK4 and Pam3CysSK4 counterparts, pointing to a different binding mode of the UPam ligands.

show abstract

Novel 1,2,3-triazole-tethered Pam3CAG conjugates as potential TLR-2 agonistic vaccine adjuvants

Cited by 9 publications

References 38 publications

Immunopharmacological evaluation of adjuvant efficacy of Monophosphoryl lipid-A and CpG ODN with SARS-CoV-2 RBD antigen

Immunopharmacological evaluation of adjuvant efficacy of Monophosphoryl lipid-A and CpG ODN with SARS-CoV-2 RBD antigen

Synthesis and immunopharmacological evaluation of novel TLR7 agonistic triazole tethered imidazoquinolines

Mono‐Palmitoyl‐N‐Alkylurea Ligands as Specific Activators of Human Toll‐Like Receptor 2/6 Heterodimer

Contact Info

Product

Resources

About